Diagnosis and management of melanoma with regional lymph node metastases: a population‐based study in France

Abstract

Overall, actual practice was in accordance with French recommendations. The main developments from 2004 to 2008 were the disappearance of adjuvant chemotherapies and a more accurate selection of patients for adjuvant interferon.

Distinctive Features of Melanoma and Its Management in Elderly Patients

“…Most studies on melanoma in the elderly have focused on characteristics of patients and tumors; to our knowledge, none has included comprehensive data on the real management of melanoma on a population basis. Previous studies [18][19][20][21] in 2004 and 2008 provided population-based data on different aspects of diagnosis and/or management of melanoma in a large French geographic area. The present study evaluated to what extent characteristics of primary tumors and their management (including excision, surgical margins, sentinel lymph node biopsy [SLNB], adjuvant therapies, and surveillance procedures) differed in older patients compared with younger ones.…”

Mental Health Services Use by Melanoma Patients Receiving Adjuvant Interferon: Association of Pre-treatment Mental Health Care with Early Discontinuation

“…Of treated patients, 40% developed depression or other neuropsychiatric symptoms, and up to 10% of all patients required psychiatric evaluation and treatment, or dose modification 7 . Two French population-based studies reported on small groups of hd-ifn patients 8,9 ; the study by Lévy-Sitbon et al reported that 9 of 36 patients receiving hd-ifn stopped early because of toxicity. No further information about toxicity-such as its nature, timing, or management-was available for those cases.…”